Company
Headquarters: Paiania, Greece
Employees: 251
€145.4 Million
EUR as of July 1, 2024
US$156.1 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
AbbVie | $295.34 B |
AstraZeneca | $236.45 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; over the counter (OTC) drugs, such as antiseptics, and analgesics; gynecological products; and anti-lice treatment drugs. It also provides transdermal drug delivery systems (TDDS) related to pain management, hypertension, angina pectoris, Parkinson disease, asthma, female or male hormone replacement therapy, contraception, nausea, incontinence, etc. In addition, the company's product pipeline includes nicotine TDDS for smoking cessation; TDDS for hypertension; range of OTC products for common cold, oral hygiene, excessive excretion of shawl; food supplements; and anti-ageing products. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Lavipharm SA has the following listings and related stock indices.
Stock: ASE: LAVI wb_incandescent